Jianing Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianing Xie has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Gang Xue
Max-Planck-Institute of Molecular Physiology
1 shared publication - Georg E. Winter
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
1 shared publication - Hana Imrichova
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
1 shared publication - Herbert Waldmann
Department of Chemical Biology, Max Planck Institute of Molecular Physiology, Dortmund, Germany.
1 shared publication - Lara Dötsch
Max-Planck-Institute of Molecular Physiology
1 shared publication - Marko Cigler
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 10 March 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
Targeted proteasomal and autophagic protein degradation, often employing bifunctional modalities, is a new paradigm for modulation of protein function. In an attempt to explore protein degradation by means of autophagy we combined arylidene-indolinones reported to bind the autophagy related LC3B-protein and ligands of the PDE lipoprotein chaperone, the BRD2/3/4-bromodomain containing proteins and the BTK- and BLK kinases. Unexpectedly, the resulting bifunctional degraders do not induce protein degradation by means of macroautophagy, but instead direct their targets to the ubiquitin-proteasome system. Target and mechanism identification revealed that the arylidene-indolinones covalently bind DCAF11, a substrate receptor in the CUL4A-RBX1-DDB1-DCAF11 E3 ligase. The tempered -unsaturated indolinone electrophiles define a novel drug-like DCAF11-ligand class that enables exploration of this E3 ligase in chemical biology and medicinal chemistry programs. The arylidene-indolinone scaffold frequently occurs in natural products which raises the question whether novel E3 ligand classes can be found more widely among natural products and related compounds.
- 10 March 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
Targeted proteasomal and autophagic protein degradation, often employing bifunctional modalities, is a new paradigm for modulation of protein function. In an attempt to explore protein degradation by means of autophagy we combined arylidene-indolinones reported to bind the autophagy related LC3B-protein and ligands of the PDE lipoprotein chaperone, the BRD2/3/4-bromodomain containing proteins and the BTK- and BLK kinases. Unexpectedly, the resulting bifunctional degraders do not induce protein degradation by means of macroautophagy, but instead direct their targets to the ubiquitin-proteasome system. Target and mechanism identification revealed that the arylidene-indolinones covalently bind DCAF11, a substrate receptor in the CUL4A-RBX1-DDB1-DCAF11 E3 ligase. The tempered -unsaturated indolinone electrophiles define a novel drug-like DCAF11-ligand class that enables exploration of this E3 ligase in chemical biology and medicinal chemistry programs. The arylidene-indolinone scaffold frequently occurs in natural products which raises the question whether novel E3 ligand classes can be found more widely among natural products and related compounds.